Sign In
Buy OGN
$13.49
-0.0100 (-0.0741%)
At Close: Jul 15, 2026
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 15'th Jul 2026
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Orogen Royalties Begins Trading on OTCQX Best Market
08:00am, Friday, 10'th Jul 2026
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Orogen Royalties Inc. (TSXV:OGN)(OTCQX:OGNNF) ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading on th
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:01am, Friday, 03'rd Jul 2026
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders?
02:00pm, Thursday, 25'th Jun 2026
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
03:00pm, Wednesday, 24'th Jun 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
02:28pm, Wednesday, 24'th Jun 2026
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:02am, Monday, 22'nd Jun 2026
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
07:30am, Monday, 22'nd Jun 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Ca
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
10:16am, Friday, 12'th Jun 2026
OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.
Organon wins US approval to widen use of arthritis biosimilar drug
08:44am, Wednesday, 10'th Jun 2026
Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a life‑threatening immune reactio
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 09'th Jun 2026
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
01:13pm, Thursday, 04'th Jun 2026
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
11:16am, Thursday, 04'th Jun 2026
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
